The role of small leucine-rich proteoglycans in osteoarthritis pathogenesis

Osteoarthritis and Cartilage

Volumn 22, Issue 7, 2014, Pages 896-903

  Ni, G X ^a   Li, Z ^a   Zhou, Y Z ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Osteoarthritis; Pathogenesis; Small leucine rich repeat proteoglycans

Indexed keywords

CELL SURFACE RECEPTOR; COLLAGEN FIBRIL; GROWTH FACTOR; PROTEOGLYCAN; SMALL LEUCINE RICH PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; LEUCINE;

BIOLOGICAL FUNCTIONS; CELL FUNCTION; DISEASE COURSE; DISEASE MODEL; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; INNATE IMMUNITY; MOUSE MODEL; MUSCLE WEAKNESS; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; LEUCINE; MICE; OSTEOARTHRITIS; PROTEOGLYCANS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84903760623     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.04.026     Document Type: Review

References (81)

1. Internet Data Base (IDB). United States Census Bureau. Available via URL:. Accessed 2008. http://www.census.gov/ipc/www/idb/worldpop.html.
2. Gupta S., Hawker G.A., Laporte A., Croxford R., Coyte P.C. The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatol (Oxford) 2005, 44:1531-1537.
3. Bos S.D., Slagboom P.E., Meulenbelt I. New insights into osteoarthritis: early developmental features of an ageing-related disease. Curr Opin Rheumatol 2008, 20:553-559.
4. Cornelis F.M., Luyten F.P., Lories R.J. Functional effects of susceptibility genes in osteoarthritis. Discov Med 2011, 12:129-139.
5. Valdes A.M., Spector T.D. The clinical relevance of genetic susceptibility to osteoarthritis. Best Pract Res Clin Rheumatol 2010, 24:3-14.
6. Valdes A.M., Spector T.D. Genetic epidemiology of hip and knee osteoarthritis. Nat Rev Rheumatol 2011, 7:23-32.
7. Iozzo R.V. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 1997, 32:141-174.
8. Ameye L., Young M.F. Mice deficient in small leucine-rich proteoglycans: novel invivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 2002, 12:107R-116R.
9. Reed C.C., Iozzo R.V. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 2002, 19:249-255.
10. Nikitovic D., Berdiaki K., Chalkiadaki G., Karamanos N., Tzanakakis G. The role of SLRP-Proteoglycans in osteosarcoma pathogenesis. Connect Tissue Res 2008, 49:235-238.
11. Flannery C.R. Usurped SLRPs: novel arthritis biomarkers exposed by catabolism of small leucine-rich proteoglycans?. Arthritis Res Ther 2006, 8:106.
12. Kjellén L., Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991, 60:443-475.
13. Raspanti M., Congiu T., Alessandrini A., Gobbi P., Ruggeri A. Different patterns of collagen-proteoglycan interaction: a scanning electron microscopy and atomic force microscopy study. Eur J Histochem 2000, 44:335-343.
14. Schaefer L., Iozzo R.V. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. JBiol Chem 2008, 283:21305-21309.
15. McEwan P.A., Scott P.G., Bishop P.N., Bella J. Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. JStruct Biol 2006, 155:294-305.
16. Day A.A., McQuillan C.I., Termine J.D., Young M.R. Molecular cloning and sequence analysis of the cDNA for small proteoglycan II of bovine bone. Biochem J 1987, 248:801-805.
17. Merline R., Schaefer R.M., Schaefer L. The matricellular functions of small leucine-rich proteoglycans (SLRPs). JCell Commun Signal 2009, 3:323-335.
18. Kalamajski S., Oldberg Å. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol 2010, 29:248-253.
19. Dellett M., Hu W., Papadaki V., Ohnuma S. Small leucine rich proteoglycan family regulates multiple signalling pathways in neural development and maintenance. Dev Growth Differ 2012, 54:327-340.
20. Ezura Y., Chakravarti S., Oldberg A., Chervoneva I., Birk D.E. Differential expression of lumican and fibromodulin regulate collagen fibrillogenesis in developing mouse tendons. JCell Biol 2000, 151:779-788.
21. Zhang G., Ezura Y., Chervoneva I., Robinson P.S., Beason D.P., Carine E.T., et al. Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. JCell Biochem 2006, 98:1436-1449.
22. Geng Y., McQuillan D., Roughley P.J. SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol 2006, 25:484-491.
23. Hildebrand A., Romarís M., Rasmussen L.M., Heinegård D., Twardzik D.R., Border W.A., et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994, 302(Pt 2):527-534.
24. Morris S.A., Almeida A.D., Tanaka H., Ohta K., Ohnuma S. Tsukushi modulates Xnr2, FGF and BMP signaling: regulation of Xenopus germ layer formation. PLoS One 2007, 2:e1004.
25. Inkson C.A., Ono M., Bi Y., Kuznetsov S.A., Fisher L.W., Young M.F. The potential functional interaction of biglycan and WISP-1 in controlling differentiation and proliferation of osteogenic cells. Cells Tissues Organs 2009, 189:153-157.
26. Goldoni S., Humphries A., Nystroöm A., Sattar S., Owens R.T., McQuillan D.J., et al. Decorin is a novel antagonistic ligand of the Met receptor. JCell Biol 2009, 185:743-754.
27. Malinowski M., Pietraszek K., Perreau C., Boguslawski M., Decot V., Stoltz J.F., et al. Effect of lumican on the migration of human mesenchymal stem cells and endothelial progenitor cells: involvement of matrix metalloproteinase-14. PLoS One 2012, 7:e50709.
28. Bi Y., Stuelten C.H., Kilts T., Wadhwa S., Iozzo R.V., Robey P.G., et al. Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. JBiol Chem 2005, 280:30481-30489.
29. Chen X.D., Bian X., Teslovich T.M., Stephan D.A., Young M.F. Dissection of the sets of genes that control the behavior of biglycan-deficient pre-osteoblasts using oligonucleotide microarrays. Bone 2005, 37:192-203.
30. Chang H.X., Yang L., Li Z., Chen G., Dai G. Age-related biological characterization of mesenchymal progenitor cells in human articular cartilage. Orthopedics 2011, 34:e382-e388.
31. Gerter R., Kruegel J., Miosge N. New insights into cartilage repair - the role of migratory progenitor cells in osteoarthritis. Matrix Biol 2012, 31:206-213.
32. Sjöberg A.P., Manderson G.A., Mörgelin M., Day A.J., Heinegård D., Blom A.M. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol 2009, 46:830-839.
33. Schaefer L., Babelova A., Kiss E., Hausser H.J., Baliova M., Krzyzankova M., et al. The matrix component biglycan is proinflammatory and signals through toll-like receptors 4 and 2 in macrophages. JClin Invest 2005, 115:2223-2233.
34. Lorenzo P., Aspberg A., Onnerfjord P., Bayliss M.T., Neame P.J., Heinegård D. Identification and characterization of asporin. A novel member of the leucine-rich repeat protein family closely related to decorin and biglycan. JBiol Chem 2001, 276:12201-12211.
35. Aigner T., Fundel K., Saas J., Gebhard P.M., Haag J., Weiss T., et al. Large scale gene expression profiling reveals major pathogenetic pathways of cartilage degeneration in osteoarthritis. Arthritis Rheum 2006, 54:3533-3544.
36. Monfort J., Tardif G., Roughley P., Reboul P., Boileau C., Bishop P.N., et al. Identification of opticin, a member of the small leucine-rich repeat proteoglycan family, in human articular tissues: a novel target for MMP-13 in osteoarthritis. Osteoarthritis Cartilage 2008, 16:749-755.
37. Melrose J., Fuller E.S., Roughley P.J., Smith M.M., Kerr B., Hughes C.E., et al. Fragmentation of decorin, biglycan, lumican and keratocan is elevated in degenerate human meniscus, knee and hip articular cartilages compared with age-matched macroscopically normal and control tissues. Arthritis Res Ther 2008, 10:R79.
38. Cs-Szabó G., Melching L.I., Roughley P.J., Glant T.T. Changes in messenger RNA and protein levels of proteoglycans and link protein in human osteoarthritic cartilage samples. Arthritis Rheum 1997, 40:1037-1045.
39. Bock H.C., Michaeli P., Bode C., Schultz W., Kresse H., Herken R., et al. The small proteoglycans decorin and biglycan in human articular cartilage of late-stage osteoarthritis. Osteoarthritis Cartilage 2001, 9:654-663.
40. Henry S.P., Takanosu M., Boyd T.C., Mayne P.M., Eberspaecher H., Zhou W., et al. Expression pattern and gene characterization of asporin. a newly discovered member of the leucine-rich repeat protein family. JBiol Chem 2001, 276:12212-12221.
41. Kizawa H., Kou I., Iida A., Sudo A., Miyamoto Y., Fukuda A., et al. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet 2005, 37:138-144.
42. Jiang Q., Shi D., Yi L., Ikegawa S., Wang Y., Nakamura T., et al. Replication of the association of the aspartic acid repeat polymorphism in the asporin gene with knee-osteoarthritis susceptibility in Han Chinese. JHum Genet 2006, 51:1068-1072.
43. Rodriguez-Lopez J., Pombo-Suarez M., Liz M., Gomez-Reino J.J., Gonzalez A. Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians. Arthritis Res Ther 2006, 8:R55.
44. Kaliakatsos M., Tzetis M., Kanavakis E., Fytili P., Chouliaras G., Karachalios T., et al. Asporin and knee osteoarthritis in patients of Greek origin. Osteoarthritis Cartilage 2006, 14:609-611.
45. Mustafa Z., Dowling B., Chapman K., Sinsheimer J.S., Carr A., Loughlin J. Investigating the aspartic acid (D) repeat of aspirin as a risk factor for osteoarthritis in a UK Caucasian population. Arthritis Rheum 2005, 52:3502-3506.
46. Nakamura T., Shi D., Tzetis M., Rodriguez-Lopez J., Miyamoto Y., Tsezou A., et al. Meta-analysis of association between the ASPN D-repeat and osteoarthritis. Hum Mol Genet 2007, 16:1676-1681.
47. Song J.H., Lee H.S., Kim C.J., Cho Y.G., Park Y.G., Nam S.W., et al. Aspartic acid repeat polymorphism of the asporin gene with susceptibility to osteoarthritis of the knee in a Korean population. Knee 2008, 15:191-195.
48. Xing D., Ma X.L., Ma J.X., Xu W.G., Wang J., Yang Y., et al. Association between aspartic acid repeat polymorphism of the asporin gene and susceptibility to knee osteoarthritis: a genetic meta-analysis. Osteoarthritis Cartilage 2013, 21:1700-1706.
49. Song G.G., Kim J.H., Lee Y.H. Ameta-analysis of the relationship between aspartic acid (D)-repeat polymorphisms in asporin and osteoarthritis susceptibility. Rheumatol Int 2014, in press.
50. Ameye L., Aria D., Jepsen K., Oldberg A., Xu T., Young M.F. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J 2002, 16:673-680.
51. Jepsen K., Wu F., Peragallo J.H., Paul J., Roberts L., Ezura Y., et al. Asyndrome of joint laxity and impaired tendon integrity in lumican- and fibromodulin-deficient mice. JBiol Chem 2002, 277:35532-35540.
52. Gill M.R., Oldberg A., Reinholt F.P. Fibromodulin-null murine knee joints display increased incidences of osteoarthritis and alterations in tissue biochemistry. Osteoarthritis Cartilage 2002, 10:751-757.
53. Nuka S., Zhou W., Henry S.P., Gendron C.M., Schultz J.B., Shinomura T., et al. Phenotypic characterization of epiphycan-deficient and epiphycan/biglycan double-deficient mice. Osteoarthritis Cartilage 2010, 18:88-96.
54. Xu T., Bianco P., Fisher L.W., Longenecker G., Smith E., Goldstein S., et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 1998, 20:78-82.
55. Kilts T., Ameye L., Syed-Picard F., Ono M., Berendsen A.D., Oldberg A., et al. Potential roles for the small leucine-rich proteoglycans biglycan and fibromodulin in ectopic ossification of tendon induced by exercise and in modulating rotarod performance. Scand J Med Sci Sports 2009, 19:536-546.
56. Svensson L., Aszódi A., Reinholt F.P., Fässler R., Heinegård D., Oldberg A. Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. JBiol Chem 1999, 274:9636-9647.
57. Wadhwa S., Embree M., Ameye L., Young M.F. Mice deficient in biglycan and fibromodulin as a model for temporomandibular joint osteoarthritis. Cells Tissues Organs 2005, 181:136-143.
58. Heathfield T.F., Onnerfjord P., Dahlberg L., Heinegård D. Cleavage of fibromodulin in cartilage explants involves removal of the N-terminal tyrosine sulfate-rich region by proteolysis at a site that is sensitive to matrix metalloproteinase-13. JBiol Chem 2004, 279:6286-6295.
59. Monfort J., Tardif G., Reboul P., Mineau F., Roughley P., Pelletier J.P., et al. Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site. Arthritis Res Ther 2006, 8:R26.
60. Blaney Davidson E.N., van der Kraan P.M., van den Berg W.B. TGF-beta and osteoarthritis. Osteoarthritis Cartilage 2007, 15:597-604.
61. Wadhwa S., Embree M.C., Kilts T., Young M.F., Ameye L.G. Accelerated osteoarthritis in the temporomandibular joint of biglycan/fibromodulin double-deficient mice. Osteoarthritis Cartilage 2005, 13:817-827.
62. Bi Y., Ehirchiou D., Kilts T.M., Inkson C.A., Embree M.C., Sonoyama W., et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 2007, 13:1219-1227.
63. Embree M.C., Kilts T.M., Ono M., Inkson C.A., Syed-Picard F., Karsdal M.A., et al. Biglycan and fibromodulin have essential roles in regulating chondrogenesis and extracellular matrix turnover in temporomandibular joint osteoarthritis. Am J Pathol 2010, 176:812-826.
64. Mahjoub M., Berenbaum F., Houard X. Why subchondral bone in osteoarthritis? The importance of the cartilage bone interface in osteoarthritis. Osteoporos Int 2012, 23:S841-S846.
65. Rucci N., Rufo A., Alamanou M., Capulli M., Del Fattore A., Ahrman E., et al. The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. JCell Biol 2009, 187:669-683.
66. Bennell K.L., Wrigley T.V., Hunt M.A., Lim B.W., Hinman R.S. Update on the role of muscle in the genesis and management of knee osteoarthritis. Rheum Dis Clin North Am 2013, 39:145-176.
67. Rehan Youssef A., Longino D., Seerattan R., Leonard T., Herzog W. Muscle weakness causes joint degeneration in rabbits. Osteoarthritis Cartilage 2009, 17:1228-1235.
68. Tonge D.P., Bardsley R.G., Parr T., Maciewicz R.A., Jones S.W. Evidence of changes to skeletal muscle contractile properties during the initiation of disease in the ageing guinea pig model of osteoarthritis. Longev Heal 2013, 2:15.
69. Bowe M.A., Mendis D.B., Fallon J.R. The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle. JCell Biol 2000, 148:801-810.
70. Rafii M., Creely H., McKechnie B., Ferri R., Seo N., Young M., et al. Interactions of the proteoglycan biglycan with the dystrophin-associated protein complex and its roles in muscular dystrophy and synaptogenesis. Mol Biol Cell 2000, 11(Suppl l):164a.
71. Brandan E., Cabello-Verrugio C., Vial C. Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol 2008, 27:700-708.
72. Miura T., Kishioka Y., Wakamatsu J., Hattori A., Hennebry A., Berry C.J., et al. Decorin binds myostatin and modulates its activity to muscle cells. Biochem Biophys Res Commun 2006, 340:675-680.
73. Buckland J. Osteoarthritis: complement-mediated inflammation in OA progression. Nat Rev Rheumatol 2011, 8:2.
74. Sjöberg A., Onnerfjord P., Morgelin M., Heinegård D., Blom A.M. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. JBiol Chem 2005, 280:32301-32308.
75. Groeneveld T.W., Oroszlán M., Owens R.T., Faber-Krol M.C., Bakker A.C., Arlaud G.J., et al. Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collections. JImmunol 2005, 175:4715-4723.
76. Scanzello C.R., Plaas A., Crow M.K. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?. Curr Opin Rheumatol 2008, 20:565-572.
77. Wu F., Vij N., Roberts L., Lopez-Briones S., Joyce S., Chakravarti S. Anovel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. JBiol Chem 2007, 282:26409-26417.
78. Little C.B., Zaki S. What constitutes an "animal model of osteoarthritis" - the need for consensus?. Osteoarthritis Cartilage 2012, 20:261-267.
79. Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 2006, 8:37-44.
80. Huebner J.L., Kraus V.B. Assessment of the utility of biomarkers of osteoarthritis in the guinea pig. Osteoarthritis Cartilage 2006, 14:923-930.
81. Young A.A., Smith M.M., Smith S.M., Cake M.A., Ghosh P., Read R.A., et al. Regional assessment of articular cartilage gene expression and small proteoglycan metabolism in an animal model of osteoarthritis. Arthritis Res Ther 2005, 7:R852-R861.